- Home
- GNTA vs CGTX Comparison
GNTA vs CGTX Comparison
Compare GNTA & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- CGTX
- Stock Information
- Founded
- GNTA 2014
- CGTX 2007
- Country
- GNTA Italy
- CGTX United States
- Employees
- GNTA 13
- CGTX N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- CGTX Health Care
- Exchange
- GNTA Nasdaq
- CGTX Nasdaq
- Market Cap
- GNTA 39.4M
- CGTX 158.8M
- IPO Year
- GNTA 2021
- CGTX 2021
- Fundamental
- Price
- GNTA $1.70
- CGTX $1.41
- Analyst Decision
- GNTA
- CGTX Strong Buy
- Analyst Count
- GNTA 0
- CGTX 4
- Target Price
- GNTA N/A
- CGTX $2.88
- AVG Volume (30 Days)
- GNTA 936.3K
- CGTX 1.0M
- Earning Date
- GNTA 01-01-0001
- CGTX 11-06-2025
- Dividend Yield
- GNTA N/A
- CGTX N/A
- EPS Growth
- GNTA N/A
- CGTX N/A
- EPS
- GNTA N/A
- CGTX N/A
- Revenue
- GNTA N/A
- CGTX N/A
- Revenue This Year
- GNTA N/A
- CGTX N/A
- Revenue Next Year
- GNTA N/A
- CGTX N/A
- P/E Ratio
- GNTA N/A
- CGTX N/A
- Revenue Growth
- GNTA N/A
- CGTX N/A
- 52 Week Low
- GNTA $1.35
- CGTX $0.22
- 52 Week High
- GNTA $10.00
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- GNTA 37.34
- CGTX 40.04
- Support Level
- GNTA $2.15
- CGTX $1.40
- Resistance Level
- GNTA $2.32
- CGTX $1.83
- Average True Range (ATR)
- GNTA 0.26
- CGTX 0.14
- MACD
- GNTA -0.05
- CGTX -0.03
- Stochastic Oscillator
- GNTA 32.23
- CGTX 20.74
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.